Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699

The potential impact of tumour biology on improved clinical practice for medulloblastoma: progress towards biologically driven clinical trials

(2009) Barry L. Pizer et al.   BRITISH JOURNAL OF NEUROSURGERY

Vasoactivity of AG014699, a Clinically Active Small Molecule Inhibitor of Poly(ADP-ribose) Polymerase: a Contributory Factor to Chemopotentiation In vivo?

(2009) M. Ali et al.   CLINICAL CANCER RESEARCH

Inhibition of Poly(ADP-Ribose) Polymerase-1 Enhances Temozolomide and Topotecan Activity against Childhood Neuroblastoma

(2009) R. A. Daniel et al.   CLINICAL CANCER RESEARCH

Analysis of microsatellite instability in medulloblastoma

(2009) Marta Viana-Pereira et al.   NEURO-ONCOLOGY

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers

(2009) Peter C. Fong et al.   NEW ENGLAND JOURNAL OF MEDICINE

Medulloblastoma: new insights into biology and treatment

(2008) B Pizer et al.   Archives of Disease in Childhood-Education and Practice Edition

A New Model for Prediction of Drug Distribution in Tumor and Normal Tissues: Pharmacokinetics of Temozolomide in Glioma Patients

(2008) L. Rosso et al.   CANCER RESEARCH

Efficacy of temozolomide for recurrent embryonal brain tumors in children

(2008) Chung-Hao Wang et al.   CHILDS NERVOUS SYSTEM

Phase I Study of the Poly(ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors

(2008) R. Plummer et al.   CLINICAL CANCER RESEARCH

Mechanisms of Disease: temozolomide and glioblastoma—look to the future

(2008) Maciej M Mrugala et al.   Nature clinical practice. Oncology